References
- Pines A, Sturdee DW, Birkhäuser MH, et al.;Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–94
- Rossouw JE, Anderson GL, Prentice RL, et al.;Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative. Menopause 2012;19:616–21
- Huot L, Couris CM, Tainturier V, Jaglal S, Colin C, Schott AM. Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 2008;19:1047–54
- Machado RB, Fernandes CE, Maia E, Melo NR, Baracat EC. Hormone therapy following the Women’s Health Initiative (WHI) study: perception of gynecologists in Brazil. Minerva Ginecol 2005;57:563–8
- Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
- Sarrel PM. Mortality toll due to avoiding estrogen therapy in hysterectomized women: estimates for 2002–2011. Climacteric 2013;16:718–19
- Burger HG, MacLennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women’s health. Climacteric 2012;15:281–7
- Shapiro S, Farmer RD, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: 2. The Women’s Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011;37:165–72
- Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
- Fletcher RH, Fletcher SW, Wagner EH. Risk. In Fletcher RH, Fletcher SW, Wagner EH, eds. Clinical Epidemiology: The Essentials. Baltimore: Williams & Wilkins, 1996:103–19
- Machado RB, Morimoto M, Santana N, Arruda LF, Bernardes CR, de Souza IM. Effect of information on the perception of users and prospective users of combined oral contraceptives regarding the risk of venous thromboembolism. Gynecol Endocrinol 2015;31:57–60
- Jalava-Broman J, Mäkinen J, Ojanlatva A, Jokinen K, Sillanmäki L, Rautava P. Change in the frequency of HRT use from 2000 to 2005 and reasons to discontinue: follow-up of a normal cohort in Finland. Acta Obstet Gynecol Scand 2011;90:351–7